These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3588282)

  • 21. [Virus inactivation of plasma products. Practical methods and their safety].
    Rübsamen-Waigmann H
    Dtsch Med Wochenschr; 1994 Mar; 119(10):345-8. PubMed ID: 8125038
    [No Abstract]   [Full Text] [Related]  

  • 22. [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems].
    Burnouf T; Goubran HA; Radosevich M; El-Ekiaby M
    Transfus Clin Biol; 2008 Jun; 15(3):129-34. PubMed ID: 18538608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
    Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
    Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation.
    Stephan W
    Curr Stud Hematol Blood Transfus; 1989; (56):122-7. PubMed ID: 2642784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of protein modification during anti-viral heat bioprocessing by electrospray ionization mass spectrometry.
    Smales CM; Pepper DS; James DC
    Rapid Commun Mass Spectrom; 2001; 15(5):351-6. PubMed ID: 11241766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Virus safety of labile plasma products from the German viewpoint].
    Stephan W
    Beitr Infusionsther; 1989; 24():40-5. PubMed ID: 2481547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
    Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
    Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Monitoring of sterilization procedures for plasma derivatives using bacteriophages].
    Dichtelmüller H; Stephan W
    Immun Infekt; 1988 Feb; 16(1):18-20. PubMed ID: 3283031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The possibilities and limits for virus inactivation in the household].
    Mahnel H
    Zentralbl Bakteriol Mikrobiol Hyg B Umwelthyg Krankenhaushyg Arbeitshyg Prav Med; 1989 Apr; 187(4-6):414-21. PubMed ID: 2500807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
    Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
    Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS.
    Biesert L; Suhartono H
    Vox Sang; 1998; 74 Suppl 1():207-12. PubMed ID: 9789530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro study of a triple-secured von Willebrand factor concentrate.
    Mazurier C; Poulle M; Samor B; Hilbert L; Chtourou S
    Vox Sang; 2004 Feb; 86(2):100-4. PubMed ID: 15023178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virus inactivation and protein recovery in a novel ultraviolet-C reactor.
    Wang J; Mauser A; Chao SF; Remington K; Treckmann R; Kaiser K; Pifat D; Hotta J
    Vox Sang; 2004 May; 86(4):230-8. PubMed ID: 15144527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography.
    Chen SX; Hammond DJ; Lang JM; Lebing WR
    Vox Sang; 1998; 74(4):232-41. PubMed ID: 9691404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measures to inactivate viral contaminants of pooled plasma products.
    Menache D; Aronson DL
    Prog Clin Biol Res; 1985; 182():407-23. PubMed ID: 3929261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined solvent-detergent and 100 degrees C (boiling) sterilizing dry-heat treatment of factor VIII concentrates to assure sterility.
    Rubinstein AI; Rubinstein DB; Coughlin J
    Vox Sang; 1991; 60(1):60. PubMed ID: 1905083
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
    Smith MP; Rice KM; Savidge GF
    Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
    [No Abstract]   [Full Text] [Related]  

  • 40. Chromatographic removal and heat inactivation of hepatitis B virus during the manufacture of human albumin.
    Adcock WL; MacGregor A; Davies JR; Hattarki M; Anderson DA; Goss NH
    Biotechnol Appl Biochem; 1998 Oct; 28 ( Pt 2)():169-78. PubMed ID: 9756468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.